Magnetic Iron Oxide Colloids for Environmental Applications

This chapter deals with magnetic colloids with catalytic properties for the treatment of polluted waters and the efficient production of fuel alternatives. This kind of materials presents great advantages such as high surface/volume ratio, reproducibility, selectivity, ability to be magnetic harvested, functionalizable surfaces (e.g. with tunable pores and selective chelators deposited on them), high efficiencies and reusability. In particular, this chapter will consider the case of magnetic iron oxide colloids, which can be easily synthesized at low cost, are biocompatible and presents a well-developed surface chemistry. The most common techniques for the synthesis and functionalization of these magnetic nanoparticles will be reviewed and summarized. The iron oxide nanoparticles present outstanding properties that can be exploited in different aspect of the wastewater treatment such as heavy metals and organic pollutants removal by ionic exchange or adsorption, and degradation of the contaminants by advanced oxidation processes, among others. In the field of alternative energies, they have also been used as catalysts for biofuels production from oil crops, in Fischer-Tropsch reactions for liquid hydrocarbons and many other processes with potential environmental impact

Superparamagnetic iron oxide nanoparticles decorated mesoporous silica nanosystem for combined antibiofilm therapy

A crucial challenge to face in the treatment of biofilm-associated infection is the ability of bacteria to develop resistance to traditional antimicrobial therapies based on the administration of antibiotics alone. This study aims to apply magnetic hyperthermia together with controlled antibiotic delivery from a unique magnetic-responsive nanocarrier for a combination therapy against biofilm. The design of the nanosystem is based on antibiotic-loaded mesoporous silica nanoparticles (MSNs) externally functionalized with a thermo-responsive polymer capping layer, and decorated in the outermost surface with superparamagnetic iron oxide nanoparticles (SPIONs). The SPIONs are able to generate heat upon application of an alternating magnetic field (AMF), reaching the temperature needed to induce a change in the polymer conformation from linear to globular, therefore triggering pore uncapping and the antibiotic cargo release. The microbiological assays indicated that exposure of E. coli biofilms to 200 µg/mL of the nanosystem and the application of an AMF (202 kHz, 30 mT) decreased the number of viable bacteria by 4 log10 units compared with the control. The results of the present study show that combined hyperthermia and antibiotic treatment is a promising approach for the effective management of biofilm-associated infections.Depto. de Química en Ciencias FarmacéuticasFac. de FarmaciaTRUEpu

Iron oxide and iron oxyhydroxide nanoparticles impair SARS-CoV-2 infection of cultured cells

Background Coronaviruses usually cause mild respiratory disease in humans but as seen recently, some human coronaviruses can cause more severe diseases, such as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the global spread of which has resulted in the ongoing coronavirus pandemic. Results In this study we analyzed the potential of using iron oxide nanoparticles (IONPs) coated with biocompatible molecules like dimercaptosuccinic acid (DMSA), 3-aminopropyl triethoxysilane (APS) or carboxydextran (FeraSpin™ R), as well as iron oxyhydroxide nanoparticles (IOHNPs) coated with sucrose (Venofer®), or iron salts (ferric ammonium citrate -FAC), to treat and/or prevent SARS-CoV-2 infection. At non-cytotoxic doses, IONPs and IOHNPs impaired virus replication and transcription, and the production of infectious viruses in vitro, either when the cells were treated prior to or after infection, although with different efficiencies. Moreover, our data suggest that SARS-CoV-2 infection affects the expression of genes involved in cellular iron metabolism. Furthermore, the treatment of cells with IONPs and IOHNPs affects oxidative stress and iron metabolism to different extents, likely influencing virus replication and production. Interestingly, some of the nanoparticles used in this work have already been approved for their use in humans as anti-anemic treatments, such as the IOHNP Venofer®, and as contrast agents for magnetic resonance imaging in small animals like mice, such as the FeraSpin™ R IONP. Conclusions Therefore, our results suggest that IONPs and IOHNPs may be repurposed to be used as prophylactic or therapeutic treatments in order to combat SARS-CoV-2 infection.This work was supported by the following Grants: CSIC-COV19-012/012202020E154 funded by the Spanish National Research Council Interdisciplinary Thematic Platform (PTI) Global Health (PTI Salud Global), SGL2103021 funded by the European Commission-NextGenerationEU (Regulation EU2020/2094) through CSIC’s Global Health Platform (PTI Salud Global); PDC2021-120759-100 funded by MCIN/AEI/10. 13039/50110 00110 33 and by the “European Union NextGenerationEU/PRTR”, PID2020-112685RB-100 funded by MCIN/AEI/10. 13039/50110 00110 33, and the “Atracción de Talento Investigador” programme (2017-T1/BMD-5155) funded by the “Comunidad de Madrid”. Y. Portilla was first a predoctoral FPU scholar (FPU15/06170) funded by MCIN/AEI/10. 13039/50110 00110 33 and by “ESF Investing in your future”, then a predoctoral scholar funded by CSIC-COV19-012/012202020E154 and is now a postdoctoral scholar funded by the European Commission-NextGenerationEU (Regulation EU2020/2094) through the CSIC’s Global Health Platform (PTI Salud Global, SGL2103021). D. López-García received a JAE-INTRO 2020 Fellowship from the Spanish National Research Council (CSIC, JAEINT-20-01805). V. Mulens-Arias was a postdoctoral scholar working under a Juan de La Cierva-Incorporación Contract (IJCI-2017-31447) funded by MCIN/AEI/10. 13039/50110 00110 33. N. Daviu is a predoctoral scholar (FPU18/04828) funded by MCIN/AEI/10. 13039/50110 00110 33 and by “ESF Investing in your future”. This research work was performed in the framework of the Nanomedicine CSIC HUB (ref. 202180E048).Peer reviewe

X-ray spectra of sources in the 13H XMM-Newton / Chandra deep field

We present the X-ray spectra of 86 optically-identified sources in the 13H XMM-Newton/Chandra deep field which have >70 X-ray counts. The sample consists of 50 broad line AGN, 25 narrow emission line galaxies, 6 absorption line galaxies, and 5 Galactic stars. The majority (42/50) of the broad line AGN have X-ray spectra which are consistent with a power law shape. They have a mean photon index of Gamma = 2.0 +- 0.1 and an intrinsic dispersion sigma = 0.4 +- 0.1. Five BLAGN show a deficit of soft X-rays, indicating absorption. Significant absorption is more common in the narrow emission line galaxies (13/25) and absorption line galaxies (2/6) than in the broad line AGN (5/50), but is not universal in any of these classes of object. The majority of the 20 absorbed sources have X-ray spectra consistent with a simple cold photoelectric absorber, but 6/20 require more complex models with either an additional component of soft X-ray emitting plasma, or an ionised absorber. Of the 16 galaxies which do not show evidence for X-ray absorption, only 2 objects are likely to be powered by star formation, and both have 2-10 keV X-ray luminosities of <= 10^40 cgs. The X-ray emission in the other 14 unabsorbed NELGs and galaxies is most likely powered by AGN, which are not detected in the optical because they are outshone by their luminous host galaxies. The Galactic stars show multi-temperature thermal spectra which peak between 0.5 and 1 keV. Star/AGN discrimination is possible for 4 of the 5 stars solely from their X-ray spectra.Comment: Accepted for publication in MNRA

Global wealth disparities drive adherence to COVID-safe pathways in head and neck cancer surgery

Peer reviewe

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks